BCT Presents 'The Haunting of Hill House'

Print Story | Email Story
BENNINGTON, VT. — Bennington Community Theater presents "The Haunting of Hill House" by F. Andrew Leslie.
The play is directed to Robert Ebert.
According to a press release:
Hoping to cause a sensation in the field of parapsychology, Dr. John Montague rents Hill House, a secluded manor with a reputation for being haunted. He carefully selects two participants for his study—Eleanor Vance, a thirty-two-year-old woman who was reported to have had experiences with a poltergeist as a child, and Theodora, a woman marked in one of his lab's studies as having psychic abilities. A third participant, Luke Sanderson, also joins the group. Luke stands to inherit Hill House after his aunt dies, and Luke's aunt sends him to watch over the house and deter amateur ghost hunters.
From the director:
I am excited to be a part of Bennington Community Theater's first stage production since the advent of the COVID-19 pandemic.  Our play, "The Haunting of Hill House" was written by F. Andrew Leslie; it is based on the novel of the same name, written by Shirley Jackson when she was living in North Bennington.  It is said that from her house she could see both the Jennings Mansion on the Bennington College campus and the Park McCullough house and that both these homes were her inspiration for Hill House.  Although she would not consider it a ‘ghost story' there is still plenty to fear in "The Haunting" and it is fitting that our opening weekend coincides with the festivities of Halloween. I am also proud and honored to be able to dedicate our production to our dear departed friend Sally Sugarman. A noted educator, Sally, along with her husband, local playwright Bob Sugarman, was an energetic devotee and advocate of live theater and she fully recognized the value of community theater. She is missed.
  • 7:30 pm Oct. 29 & 30 and Nov. 5 & 6
  • 2:00 pm Oct. 31 & Nov. 7
Tickets General Admission $10 / Premium Reserved Seating $15. Get tickets at bpacvt.org/tickets or call the box office at 802.447.0564
COVID: Proof of COVID vaccination or a negative test within 72 hours of attendance is needed to attend. A mask is required to be worn when in the theater.
iBerkshires.com welcomes critical, respectful dialogue; please keep comments focused on the issues and not on personalities. Profanity, obscenity, racist language and harassment are not allowed. iBerkshires reserves the right to ban commenters or remove commenting on any article at any time. Concerns may be sent to info@iberkshires.com.

New Oral Antivirals for COVID-19 on the Horizon

Submitted by SVMC Chief Medical Officer Trey Dobso
Patients with COVID-19 deemed to be at high risk for severe disease are currently eligible for intravenous monoclonal antibody treatments provided at certain health care systems, typically in hospitals. These medications are administered over a period of about an hour in an infusion center staffed by nurses and doctors.
When given early in the disease, they reduce the chances by as much as 70 percent that an individual with COVID-19 will require hospitalization. Yet, there are several reasons why this treatment alone is far from ideal and not sustainable in controlling the disease.
The monoclonal antibodies for COVID-19 are expensive to manufacture; although, the direct cost goes to the federal government rather than the individual. They must be given intravenously or injected under the skin in a medical setting using nurses and resources from an already strained heath care system. Obtaining the medication remains arduous, requiring testing, contacting a doctor to provide an order, scheduling a time at a select center offering the infusion, and arranging transportation, steps that favor the affluent who have contacts and resources to help in the process. The medications also have strict storage criteria and can run short during times of high demand. It is clear we need something better.
You likely heard a few weeks ago that pharmaceutical companies Merck and Ridgeback provided data on the use of an oral antiviral called molnupiravir created at Emory University in Atlanta. The medication is named after Thor's hammer, Mjolnir, to imply the drug is a hammer against SARS-CoV-2.
View Full Story

More Vermont Stories